US/UK/Canada

Share

About Us

Mertiva AB (former Diamyd Medical) primarily consists of holdings in liquid assets and holdings in Protein Sciences Corporation and Mercodia AB. Mertiva (former Diamyd Medical) shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL).

Pick a time period -
Tags ( Active)

TrialNet presents results from a study with Diamyd®

Diamyd Medical AB reports that the results of a study with the Company’s antigen-based diabetes therapy Diamyd®, conducted by the research consortium Type 1 Diabetes TrialNet did not show a statistically significant effect of the study drug.The American research consortium Type 1 Diabetes TrialNet presented their results of a Phase II study with the antigen-based diabetes therapy Diamyd® yesterday, June 27, at the American Diabetes Association 71st Scientific Sessions (ADA) in San Diego, California, USA, after the closing of the stock market. At the same time a research article about the

Diamyd informs in quarterly report of the objective to file for market approval for the Diamyd® diabetes vaccine in 2011

In her comments in today’s quarterly report Elisabeth Lindner, President and CEO of Diamyd Medical, says that the Company’s objective is to file the Diamyd® diabetes vaccine for market approval in 2011 - a goal that isn’t very far off now.During the first quarter Diamyd Medical has reported several important events that have contributed positively to the Company’s development. The financial position has been strengthened through an oversubscribed preferential rights issue, which brought in just over MSEK 219 before issue expenses. The European Phase III study with Diamyd® has been fully

Diamyd® vaccine approved for studies in children down to 3 years of age in the US

Diamyd Medical reports today that the United States Food and Drug Administration (FDA) has approved the experimental use of Diamyd® vaccine in children as young as 3 years of age in the TrialNet GAD study, enrolling 126 new onset type 1 diabetes patients in North America.The TrialNet GAD study, conducted by an international network of leading pediatric and adult endocrinologists and immunologists, has previously enrolled new onset type 1 diabetes patients from 16 to 45 years of age but is now allowed by the FDA to enroll and administer the Diamyd® vaccine to children as young as 3 years of

TrialNet Centers Begin Diamyd® Vaccine Study for Recent-Onset Type 1 Diabetes

Diamyd Medical announces today that Type 1 Diabetes TrialNet, a clinical network funded by the National Institutes of Health to prevent and treat newly diagnosed type 1 diabetes, has started recruiting patients for a clinical trial testing the Diamyd®-vaccine’s therapeutic benefit in individuals with recent-onset type 1 diabetes.The study will, as previously announced, assess the vaccine’s ability to protect and preserve insulin-secreting beta cells, which are destroyed by the body’s immune system in type 1 diabetes. Under the terms of the agreement with the National Institute of Diabetes

Diamyd® combination trial aimed at regenerating insulin-producing capacity in established type 1 diabetes gets approval from FDA

Diamyd Medical reports that the US Food and Drug Administration (FDA) has approved a study designed to preserve and possibly regenerate insulin production in patients with recent onset type 1 diabetes. The trial will test the diabetes vaccine Diamyd® in combination with drugs that are believed to stimulate new beta cell growth. The aim of the combination therapy is to try to restore lost insulin-producing capacity in established type 1 diabetes patients.The study will be carried out and funded by the National Institute of Diabetes and Kidney Disease (NIDDK), which is part of the National

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media